<DOC>
	<DOCNO>NCT02346123</DOCNO>
	<brief_summary>The purpose study analyze influence polymorphisms gene CLDN-1 ( Claudina-1 ) , LGALS3 ( Lectin galactoside-binding soluble 3 ) , SOCS3 ( Suppressor cytokine signal 3 ) , IL-28B ( interleukin-28B ) , CCL5 ( Chemokine C-C ligand 5 ) determination clinical form percentage cardiac fibrosis patient Chagas disease .</brief_summary>
	<brief_title>Determination Genetic Polymorphisms Chronic Chagas Cardiomyopathy</brief_title>
	<detailed_description>The Chagas disease , chronic phase , lead development cardiac arrhythmia dilate cardiomyopathy , evolve heart failure , cause great morbidity reduction patient 's quality life . Some patient stay asymptomatic others develop cardiac form disease ( chronic chagasic cardiomyopathy ) , form , like digestive ( megacolon megaesophagus ) mixed form ( cardiac digestive ) . The objective study analyze association single nucleotide polymorphisms clinical form amount cardiac fibrosis patient Chagas disease . The polymorphism analyze real time PCR ( Polymerase Chain Reaction ) . The gene whose polymorphism analyze : galectin-3 , SOCS-3 , IL-28B , CLDN-1 CCL5 . The patient shall accompany specialized outpatient clinic Chagas disease - Center Biotechnology Cell Therapy . They submit collection blood sample biochemical analysis cardiac magnetic resonance imaging .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Chagas Cardiomyopathy</mesh_term>
	<criteria>Chagas disease diagnosis confirm 2 different serology Diagnosis Chagas disease form : indeterminate cardiac one , without ventricular dysfunction Significant aortic stenosis Mitral stenosis valve area inferior 1,5 cm2 Superior moderate aortic and/or mitral regurgitation Chronic use immunosuppressive agent Dialysis treatment terminal renal failure Fever last 48 hour evidence systemic infection activity Current abusive use alcohol illicit drug Any comorbidities impact patient 's survival within next 2 year Liver disease activity Continuous use steroid treatment chronic obstructive pulmonary disease Hematologic , neoplastic bone diseases Homeostasis disturbance Inflammatory diseases chronic infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chagas disease</keyword>
	<keyword>Polymorphisms</keyword>
	<keyword>Biomarkers</keyword>
</DOC>